Ryverna (Crizanlizumab)

We are currently not shipping Ryverna.

Adakveo is manufactured by Novartis under the name Ryverna for emerging markets.  

Manufacturer: Novartis Pharma GmbH Roonstrasse 25 90429 Nuremberg Germany

Information about Ryverna (Crizanlizumab)

Ryverna (crizanlizumab) is a monoclonal antibody used to treat sickle cell disease (SCD), a genetic blood disorder characterized by the production of abnormal hemoglobin, which can cause red blood cells to become stiff and sickle-shaped. Crizanlizumab works by targeting and blocking the P-selectin protein, which plays a key role in the adhesion of sickle-shaped red blood cells to the blood vessel walls. This process helps decrease the frequency of painful vaso-occlusive crises (VOCs) linked to SCD. 

Product Highlights

• Ryverna is indicated for the prevention of vaso-occlusive crises (painful episodes) in patients with sickle cell disease, including both adults and pediatric patients aged 16 and older. 
• VOCs are a hallmark of SCD and can lead to hospitalizations and significant pain.

Key Ingredient

• Crizanlizumab

Key Benefits

• Ryverna significantly reduces the frequency of vaso-occlusive crises (VOCs), which are one of the most common and debilitating complications of sickle cell disease.
• By reducing the frequency of VOCs, Ryverna helps improve the overall quality of life for patients with sickle cell disease, decreasing the need for hospital visits and reducing pain.
• Regular use of Ryverna has been shown to reduce the number of hospitalizations due to VOCs in people with sickle cell disease.
• As a monoclonal antibody, Ryverna is a highly specific therapy that targets the root cause of sickle cell disease-related pain at the cellular level, making it an effective treatment option.
• Ryverna has been approved for use in both adults and pediatric patients (aged 16 years and older), making it a versatile treatment for different age groups.

Direction of Use

• The suggested dose of Ryverna is 5 mg/kg of body weight, administered through an intravenous infusion. 
• The first dose is typically given as an intravenous infusion over a period of time, followed by additional doses every 4 weeks.
• Ryverna is administered by a healthcare professional via an intravenous infusion. The infusion is typically given in a clinical setting, and patients should be monitored during the infusion for any reactions.
• Regular follow-up appointments should be scheduled to assess the drug’s effectiveness in preventing VOCs and to monitor for potential side effects.

Safety Concerns

• Some patients may experience reactions during or after the infusion, including fever, chills, shortness of breath, or hypotension (low blood pressure). These reactions can usually be managed with supportive care or changes in the infusion rate.
• As a monoclonal antibody, crizanlizumab may suppress certain immune functions, leading to a higher risk of infections. Patients should be monitored for signs of infections and treated promptly if needed.
• Although rare, some patients may experience allergic reactions to Ryverna, including rash, swelling, or difficulty breathing. Severe reactions require prompt medical attention. 
• The safety of Ryverna during pregnancy and breastfeeding has not been well-established. Patients who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Ryverna.
• Certain patients may experience alterations in their blood counts. Regular blood tests should be conducted to monitor for any abnormal results, such as low blood cell counts.

Avoid Ryverna (Crizanlizumab) If

• Do not use Ryverna if you have had a known severe allergic reaction to crizanlizumab or any of its components.
• If you have a current or recent serious infection, it may not be safe to use Ryverna. Treatment for infections should be completed before starting therapy.
• Ryverna should only be used during pregnancy if absolutely necessary. Women who are breastfeeding should avoid using Ryverna or discuss potential risks with their healthcare provider.
• If you have previously experienced severe reactions during the infusion of Ryverna, it may not be appropriate to continue treatment without medical guidance.
• Since Ryverna may affect immune function, it should be used with caution or avoided in patients with significantly weakened immune systems (e.g., HIV/AIDS or certain cancers) unless deemed necessary by a healthcare provider.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.